Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CARDIOPROTECTION

Circadian regulators as a therapeutic target in MI

Short-term targeting of the circadian regulator REV-ERB with the agonist SR9009 promotes cardiac repair after ischaemia–reperfusion injury in mice, according to a new study. These cardioprotective effects are mediated by repression of inflammatory responses. Treatment with SR9009 for just 1 day after myocardial ischaemia–reperfusion in mice increased the transcriptional repressor activity of REV-ERB and reduced the mRNA levels of cytokines and the NLRP3 inflammasome. Treated mice had less recruitment of immune cells to the infarct, reduced infarct size, less adverse remodelling and were protected against heart failure development compared with untreated mice. By contrast, SR9009 treatment in mice with REV-ERB deficiency did not impart cardioprotective benefits. Further analyses showed that cardiac fibroblasts were the cellular targets contributing to these cardioprotective effects.

References

Original article

  1. Reitz, C. J. et al. SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome. Commun. Biol. 2, 353 (2019)

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Irene Fernández-Ruiz.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fernández-Ruiz, I. Circadian regulators as a therapeutic target in MI. Nat Rev Cardiol 17, 6 (2020). https://doi.org/10.1038/s41569-019-0303-1

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing